Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Entero Therapeutics Inc ENTO

Healthcare Biotechnology
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of... see more

Recent & Breaking News (NDAQ:ENTO)

AzurRx BioPharma Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire March 8, 2021

AzurRx BioPharma to Participate in the 33rd Annual Roth Conference

GlobeNewswire March 8, 2021

AzurRx BioPharma to Participate in "Fireside Chat" at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 2, 2021

AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors

GlobeNewswire February 24, 2021

AzurRx BioPharma to Present at The Microcap Rodeo Winter Wonderland Conference

GlobeNewswire February 16, 2021

AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections

GlobeNewswire February 9, 2021

AzurRx BioPharma to Present at BIO CEO & Investor Digital Conference

GlobeNewswire February 8, 2021

AzurRx BioPharma Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS1819

GlobeNewswire January 28, 2021

AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients

GlobeNewswire January 26, 2021

AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients

GlobeNewswire January 21, 2021

AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections

GlobeNewswire January 12, 2021

AzurRx BioPharma CEO Issues Letter to Shareholders

GlobeNewswire January 8, 2021

AzurRx BioPharma to Participate in Biotech Showcase Digital 2021 Conference

GlobeNewswire January 7, 2021

AzurRx BioPharma to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference

GlobeNewswire January 6, 2021

AzurRx BioPharma to Participate in 10th Annual LifeSci Partners Corporate Access Event

GlobeNewswire January 5, 2021

AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections

GlobeNewswire January 4, 2021

AzurRx BioPharma Announces $8.0 Million Offerings

GlobeNewswire January 4, 2021

AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

GlobeNewswire November 30, 2020

InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President & CEO James Sapirstein

GlobeNewswire November 24, 2020

AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients

GlobeNewswire November 17, 2020